Cancer Center Support Grant

项目概要：总体 弗雷德哈钦森/华盛顿大学癌症联盟（“联盟”）汇集了更多 600多名成员在与癌症有关的基础，临床和公共卫生科学方面具有研究兴趣。的 该联盟的目标是消除癌症作为痛苦和死亡的原因，通过更有效的 预防，诊断和治疗，源于对疾病生物学的基本见解。的 在癌症研究学科的伙伴机构之间进行广泛的跨学科合作， 基础、临床和公共卫生科学提供了新的机会，以减少疾病的痛苦和死亡率。 癌 该联盟成立于2002年，旨在建立三个互补的优势和资源 伙伴机构：弗雷德哈奇，这一直是一个国家癌症研究所指定的综合癌症中心，自 1976年;华盛顿大学，在癌症研究，临床护理和 教学;和西雅图儿童，在该地区的主要儿科学术中心。2008年，西雅图癌症 由三家创始机构共同创立并共同拥有的癌症治疗中心Care Alliance， 被正式添加到癌症中心名称中。 该联盟的总资金基础（直接美元）为2.42亿美元，其中1.17亿美元是同行评审的，包括 NCI的5000万美元。在上一个赠款期间，超过170名新教师加入了联盟，增加了 我们的研究和临床能力的广度和深度。最近一年，我们招募了1，338名患者 介入治疗试验，其中超过50%是由药物启动的。应计项目与 新登记患者占28%。 该联盟服务于华盛顿西部13个县的集水区。这相当于该地区在 我们83%的病人都住在那里作为唯一一个NCI指定的综合癌症中心，在一个五- 州地区（华盛顿，怀俄明州，阿拉斯加州，蒙大拿州和爱达荷州），我们不仅寻求服务的健康需求 通过研究、培训和推广，扩大集水区的影响，同时确保在整个 更大的区域。 该联盟继续建立在基础癌症生物学，免疫学和 移植，病原体相关恶性肿瘤，肿瘤特异性转化研究，计算 生物学和癌症病因学，预防和结果的研究。该财团准备继续其 在这些领域的研究水平。CCSG继续对财团产生很大影响， 促进新的机构间合作，加强转化研究平台， 加强对集水区问题的研究。伙伴机构捐助了近1.2美元 在上一个项目期间，我们获得了10亿美元的机构支持，包括对我们的实验室和临床研究的投资。 研究基础设施以及教师招聘和学员支持。

PROJECT SUMMARY: OVERALL The Fred Hutchinson/University of Washington Cancer Consortium (“the Consortium”) brings together more than 600 members with research interests in basic, clinical and public health sciences related to cancer. The goal of the Consortium is the elimination of cancer as a cause of suffering and death through more effective prevention, diagnostics, and treatment, deriving from fundamental insights into the biology of the disease. The extensive interdisciplinary collaboration among the partner institutions in the cancer research disciplines of basic, clinical, and public health sciences affords new opportunities to reduce suffering and mortality from cancer. The Consortium was established in 2002 to build upon the complementary strengths and resources of three partner institutions: the Fred Hutch, which has been an NCI-designated Comprehensive Cancer Center since 1976; the University of Washington, which has significant strength in cancer research, clinical care, and teaching; and Seattle Children’s, the major pediatric academic center in the region. In 2008, the Seattle Cancer Care Alliance, the cancer treatment center founded and equally co-owned by the three founding institutions, was formally added to the cancer center designation. The Consortium’s total funding base (direct dollars) is $242M, of which $117M is peer-reviewed, including $50M from the NCI. During the last grant period, over 170 new faculty members joined the Consortium, adding breadth and depth to our research and clinical capabilities. In the most recent year, we enrolled 1,338 patients onto interventional treatment trials, of which more than 50% were investigator-initiated. The ratio of accruals to newly registered patients was 28%. The Consortium serves a catchment area of 13 counties in western Washington. This equates to the region in which 83 percent of our patients reside. As the only NCI-designated comprehensive cancer center in a five- state region (Washington, Wyoming, Alaska, Montana and Idaho), we not only seek to serve the health needs of the catchment area through research, training, and outreach, but also to ensure high impact throughout the larger region. The Consortium continues to build upon historic strengths in basic cancer biology, immunology and transplantation, pathogen associated malignancies, tumor specific translational research, computational biology and studies of cancer etiology, prevention, and outcomes. The Consortium is well poised to continue its exceptional level of research in these areas. The CCSG continues to have a high impact on the Consortium, fostering new inter-institutional collaborations, strengthening the translational research platform, and intensifying research efforts on problems of the catchment area. Partner institutions contributed nearly $1.2 billion in institutional support during the last project period, including investments in our laboratory and clinical research infrastructure as well as in faculty recruitment and trainee support.